CCL2 and atherosclerosis: Together, these findings strongly indicate that galectin-3 acts as a negative regulator of inflammation by modulating TGFβ signaling and reducing the expression of the proinflammatory molecules MMP12, CCL2, and PTGS2 in a mouse model of atherosclerosis.